2025³â 11¿ù 13ÀÏ ¸ñ¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > ´º½ºÁö´åÄÄ > Business

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýȰ

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óǰ

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
- - - - - - -
 

Novotech Recognized for Excellence in Business Expansion, Innovation, and Marketing at the 2024 Clinical Trials Arena Excellence Awards

´º½ºÀÏÀÚ: 2024-11-18

SYDNEY -- Novotech, the global full-service clinical Contract Research Organization (CRO), received multiple awards in the 2024 Clinical Trials Arena Excellence Awards, recognizing the achievements of our people in Business Expansion, Innovation, and Marketing. These awards highlight our commitment to advancing the clinical trial landscape and delivering specialized solutions across the biotech sector.

“We’re grateful for this recognition, which is a direct result of our team’s effort and commitment to our mission,” states Dr. John Moller, CEO, Novotech. “It’s a reminder of what we can accomplish when we work together, and we look forward to continuing this momentum.”

The Clinical Trials Arena Excellence Awards celebrate the pharmaceutical industry’s top achievements, identifying organizations that drive progress and innovation. Novotech’s accolades reflect our proactive strategies, technological advancements, and strong international presence.

Highlights of Novotech’s Award-Winning Strategies:

· Business Expansion - Novotech has significantly extended our reach through strategic acquisitions, including NCGS, EastHORN, and CBR International. These acquisitions have strengthened our operational capabilities and broadened service offerings, ensuring localized expertise in key biotech hubs. The launch of the Early Phase Strategic Delivery Unit (EP SDU) enhances trial support for biotech companies by leveraging Australia and New Zealand’s clinical excellence and regulatory efficiencies.

· Innovation in Data-Driven Trials - Novotech’s innovation award reflects its adoption of advanced technologies, including AI and big data analytics, which streamline trial design and execution. Partnerships with Medidata and ObvioHealth have strengthened our capacity for virtual trials and predictive analytics, leading to better site selection, faster patient recruitment, and improved trial outcomes.

· Strategic Marketing Leadership
- Under the direction of Toyna Chin, Global Director of Marketing, Novotech’s rebranding has elevated the company’s brand position as a global CRO leader. Strategic, multi-channel campaigns have increased brand recognition and positioned Novotech as a trusted partner, particularly within the US and European markets.

“I am deeply honored to accept this recognition, but it truly reflects the remarkable dedication and talent of our entire marketing organization. Their relentless effort and collaboration are what make our success possible. This award is a tribute to the passion and unity that drives us forward, proving that true marketing excellence is always the result of a collective vision and shared purpose.” - Toyna Chin, Global Director of Marketing, Novotech



 Àüü´º½º¸ñ·ÏÀ¸·Î

ChipAgents Raises Oversubscribed $21M Series A to Redefine AI for Chip Design
Bruce ATS Integrates with Yonhap Infomax to Expand 24-Hour U.S. Equities Market Access in Asia
Venture Global Statement on CP2 Final Approval
Galderma Posts Record $3.74B Sales in First Nine Months of 2025, Raises Full-Year Outlook on 15% Constant Currency Growth
LG Smart Monitor Swing Redefines Spatial Boundaries in Today¡¯s Dynamic Business Environments
Enedym Inc. Secures Investment from Honda Motor Co., Ltd.
Wilmington PharmaTech Continues Expansion with Significant Investment from Curewell Capital

 

Elon Musk Engages BRIDGE UAE on Media, Tech, and AI; Invited to 2025 I...
Heidi Secures $65 Million USD in Series B Funding to Accelerate Buildi...
HistoSonics Expands Insurance Coverage for Non-Invasive Liver Tumor Tr...
Kioxia and Sandisk Announce Beginning of Operation of Fab2 at Kitakami...
NetApp Collaborates with Cisco on Enterprise-Grade Converged Infrastru...
Interactive Brokers Launches Ask IBKR: AI Tool Delivers Instant Portfo...
Multiply Group Announces Plans to Acquire 2PointZero and Ghitha Holdin...

 


°øÁö»çÇ×
´º½ºÁö ÇÑÀÚ Ç¥±â¿¡ ´ë¸¸½Ä À½Â÷ Ç¥±â '纽ÞÙó¢ ´Ï¿ì½ÃÁö' º´±â
º£³×ÇÁ·Ò º£³×ÀÎÅõ Áß¹® Ç¥±â 宝Ò¬ÜØÙÌ 宝Ò¬ì×öõ(ÜÄÒ¬ÜØÙÌ ÜÄ...
¹Ìµð¾î¾Æ¿ì¾î Mediaour ØÚ体ä²们 ØÚô÷ä²Ùú MO ¿¥¿À ØÚä² ØÚä²
¾Ë¸®¿ìºê Alliuv ä¹备: ä¹联êó备, ¾Ë¶ã Althle ä¹÷åìÌ
¾Ë¸®¾Ë Allial Áß¹® Ç¥±â ä¹××尔 ä¹××ì³
´ºÆÛ½ºÆ® New1st Áß¹® Ç¥±â 纽ììãæ(¹øÃ¼ Òïììãæ), N1 纽1
¿£ÄÚ½º¸ð½º : À̾¾ 'EnCosmos : EC' Áß¹® Ç¥±â ì¤ñµ
¾ÆÀ̵ð¾î·Ð Idearon Áß¹® Ç¥±â ì¤îè论 ì¤îèÖå
¹ÙÀÌ¿ÀÀÌ´Ï Bioini Áß¹® Ç¥±â ù±药研 ù±å·æÚ
¿À½ºÇÁ·Ò Ausfrom 奥ÞÙÜØÙÌ, À£ÇÁ·Ò Welfrom 卫ÜØÙÌ
¿¡³ÊÇÁ·Ò Enerfrom 额ÒöÜØÙÌ ¿¡³ÊÀ¯ºñ Eneruv 额Òöêó备
¾ËÇÁ·Ò Alfrom Áß¹® Ç¥±â ä¹尔ÜØÙÌ ä¹ì³ÜØÙÌ

 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æÄ§ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇѰè¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, ÆÑ½º 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..